Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-05-03
2005-05-03
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S221000, C540S543000, C540S557000, C540S567000
Reexamination Certificate
active
06887867
ABSTRACT:
Substituted benzodiazepine compositions are provided which are active as non-NMDA ionotropic excitatory amino acid (EAA) receptor antagonists. The compounds are generally 7- or 8-mono substituted 5H-2,3-benzodiazepines. The compositions are useful for treating disorders associated with excessive activation of the non-NMDA subtype of the ionotropic EAA receptor. The compounds further are useful as testing agents to identify and characterize other compounds for the treatment of these disorders. The compounds are useful therapeutically as sedatives or for the treatment of neurosychopharmacological disorders such as stroke, ischemia and epilepsy. The compositions may be provided in combination with a suitable carrier for oral or parenteral administration. The compounds may be administered orally or parenterally for the treatment of a variety of disorders associated with non-NMDA EEA receptor function.
REFERENCES:
patent: 4614740 (1986-09-01), Lang et al.
patent: 5716956 (1998-02-01), Pelletier
patent: 6200970 (2001-03-01), Ling et al.
patent: 6323197 (2001-11-01), Csuzdi et al.
patent: WO 9728135 (1997-08-01), None
Solyom et al., Non-Competitive AMPA Antagonists of 2,3-Benzodiazepine Type, Current Pharmaceutical Design, vol. 8, No. 10, pp. 913-939, 2002.*
HCAPLUS printout of the species in WO 97/28135.*
Rona et al., Simultaneous Determination of Nerisopam, a Novel Anxiolytic Agent Showing Polymorphic Metabolism, and Its N-Acetyl Metabolite From Human Plasma by a Validated High-Performance Liquid Chromatographic Method, Journal of Chromatography B: Biomedical Applications, vol. 678, No. 1, pp. 63-72, 1996.*
Chen, “Evaluation of five methods for testing anticonvulsant activities,”Proc. Soc. Exp. Biol. Med.87:334 (1954).
Donevan & Rogawski, “GYKI 52466, a 2,3-benzodiazephine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses,”Neuron10:51-59 (1993).
Hussy, et al., “Functional properties of a cloned 5-hydroxytryptamine Ionotropic receptor subunit: Comparison with native mouse receptors,”J. Physiol. (London) 481(2):311-323 (1994).
Le Peillet, et al., “The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat,”Brain Res. 571:115-120 (1992).
Lipton & Rosenberg, “Excitatory amino acids as a final common pathway for neurologic disorders,”New England Journal of Medicine330:613-622 (1994).
McBurney, “Therapeutic potential of NMDA antagoniate in neurodegenerative diseases,”Neurobiology of Aging15:271-273 (1994).
Meldrum & Smith, “ Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat,”Stroke23:861 (1992).
Meldrum, “Excitatory amino acids in epilepsy and potential novel therapies,”Epilepsy Research12:189-196 (1992).
Remington's Pharmaceutical Sciences 17th Edition, p. 1418 (1985).
Tarnawa, et al., “Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GKYI 52466,”Eur. J. Pharmacol167:193-199 (1989).
Yamaguchi, et al., “Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models,”Epilepsy Research15:179-184 (1993).
Li Baoqing
Maccecchini Maria-Luisa
Pei Xue-Feng
Coleman Brenda
Licata & Tyrrell P.C.
Transgenomic Inc.
LandOfFree
5H-2,3-benzodiazepine antagonists of excitatory amino acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5H-2,3-benzodiazepine antagonists of excitatory amino acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5H-2,3-benzodiazepine antagonists of excitatory amino acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3403785